Carlos Bernardo Tauil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos Bernardo Tauil has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
- Yara Dadalti Fragoso
Universidade Metropolitana de Santos, Santos, Brazil
11 shared publications Marcus Vinicius Magno Goncalves
Department of Neurology, Universidade Regional de Joinville, Joinville, SC, Brazil; Department of Radiology, Universidade Regional de Joinville, Joinville, SC, Brazil
8 shared publicationsSidney Gomes
8 shared publicationsAndre Palma da Cunha Matta
Universidade Federal Fluminense, Brasil
6 shared publicationsJoseph Bruno Bidin Brooks
Universidade Metropolitana de Santos, Brasil
6 shared publications- Cintia Ramari
REVAL Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Hasselt, Belgium
5 shared publications
Latest Publications
- Open Access
- 15 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (12) , 001-008
Epidemiology and healthcare access in Brazilian multiple sclerosis patients: insights from the BRANDO database
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disorder whose prevalence varies across Brazil (from 15–27 cases per 100 thousand inhabitants), and the absence of an extensive national study limits the understanding of MS epidemiology in a nation as diverse as Brazil. To compare epidemiological data, including healthcare access, among people with MS across four Brazilian regions. Data from 2,974 Brazilian MS patients in the Collaborative Latin American Database for Multiple Sclerosis (BRANDO) were analyzed. We assessed demographic and clinical outcomes, as well as healthcare access, to elucidate regional differences. The cohort was predominantly composed of female patients (72.5%) with MS onset at a mean age of 30.6 years. Regarding the regional differences, there was a lower predominance of female patients (68.7%; p = 0.003) in the Southeast, a higher rate of subjects of mixed ethnicity (p < 0.001) in the Midwest (40.3%) and Northeast (63.7%), higher scores on the Expanded Disability Status Scale (EDSS) in the Northeast (4.0; p < 0.001), a higher prevalence of relapsing-remitting MS (RRMS) in the Southeast and Midwest (87%; p < 0.001), while the Northeast presented (p < 0.001) the highest rates of primary progressive MS (PPMS) and secondary progressive MS (SPMS) (PPMS = 15.8%; SPMS = 18%). The Northeast presented the longest time (5.9 years; p < 0.01) from disease onset until MS diagnosis (range for the other regions = 1.9–3.7 years). And the Midwest showed the shortest time (2.1 years; p < 0.01) from disease onset until first access to disease-modifying therapies (DMTs; range for the other regions = 3.5–5.1 years). The present is the first nationwide epidemiological study on people with MS in Brazil. It underscores regional epidemiological variations and differences in healthcare access, advocating for tailored approaches in MS management and research.
- 15 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (12) , 001-008
Open AccessEpidemiology and healthcare access in Brazilian multiple sclerosis patients: insights from the BRANDO database
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disorder whose prevalence varies across Brazil (from 15–27 cases per 100 thousand inhabitants), and the absence of an extensive national study limits the understanding of MS epidemiology in a nation as diverse as Brazil. To compare epidemiological data, including healthcare access, among people with MS across four Brazilian regions. Data from 2,974 Brazilian MS patients in the Collaborative Latin American Database for Multiple Sclerosis (BRANDO) were analyzed. We assessed demographic and clinical outcomes, as well as healthcare access, to elucidate regional differences. The cohort was predominantly composed of female patients (72.5%) with MS onset at a mean age of 30.6 years. Regarding the regional differences, there was a lower predominance of female patients (68.7%; p = 0.003) in the Southeast, a higher rate of subjects of mixed ethnicity (p < 0.001) in the Midwest (40.3%) and Northeast (63.7%), higher scores on the Expanded Disability Status Scale (EDSS) in the Northeast (4.0; p < 0.001), a higher prevalence of relapsing-remitting MS (RRMS) in the Southeast and Midwest (87%; p < 0.001), while the Northeast presented (p < 0.001) the highest rates of primary progressive MS (PPMS) and secondary progressive MS (SPMS) (PPMS = 15.8%; SPMS = 18%). The Northeast presented the longest time (5.9 years; p < 0.01) from disease onset until MS diagnosis (range for the other regions = 1.9–3.7 years). And the Midwest showed the shortest time (2.1 years; p < 0.01) from disease onset until first access to disease-modifying therapies (DMTs; range for the other regions = 3.5–5.1 years). The present is the first nationwide epidemiological study on people with MS in Brazil. It underscores regional epidemiological variations and differences in healthcare access, advocating for tailored approaches in MS management and research.
- Open Access
- 9 March 2025
- Published by Revista Interfaces: Saude, Humanas e Technologia in Revista Interfaces: Saúde, Humanas E Tecnologia
- Vol. 12 (4) , 4749-4759
ASSOCIATION BETWEEN PAIN AND FATIGUE IN BRAZILIAN PEOPLE WITH MULTIPLE SCLEROSIS: A CROSS‐SECTIONAL STUDY
The impact of pain and fatigue on the upper limb (UL) function of people with Multiple Sclerosis (PMS) is well-known, but the relations between them are poorly understood. This study aimed to verify the frequency of the types of pain and the relationship between pain and factors that limit UL function in PMS. This was a descriptive, cross-sectional study. Pain was evaluated by Functional Assessment of Quality of Life in PMS. UL function was evaluated by the hand grip strength and by the Test d’ Evaluation de la performance des Membres Supérieurs des Personnes Âgées (TEMPA), while the fatigue was evaluated by the Modified Fatigue Impact Scale. Correlations between pain and the other variables were analyzed with the Pearson coefficient. A simple linear regression was used to determine the influence of pain on fatigue. Sample was composed of 32 PMS diagnosed with relapsing remitting type. Muscle pain was the most common type of pain reported by participants (40%). Pain correlated strongly only with fatigue and explained 28% (R2 = 0.28) of the variance in fatigue scores. This study showed strong association between muscle pain and fatigue (r = - 0.52; p <0.01), and no association between pain and UL function. Keywords: Demyelination; symptoms; relations The impact of pain and fatigue on the upper limb (UL) function of people with Multiple Sclerosis (PMS) is well-known, but the relations between them are poorly understood. This study aimed to verify the frequency of the types of pain and the relationship between pain and factors that limit UL function in PMS. This was a descriptive, cross-sectional study. Pain was evaluated by Functional Assessment of Quality of Life in PMS. UL function was evaluated by the hand grip strength and by the Test d’ Evaluation de la performance des Membres Supérieurs des Personnes Âgées (TEMPA), while the fatigue was evaluated by the Modified Fatigue Impact Scale. Correlations between pain and the other variables were analyzed with the Pearson coefficient. A simple linear regression was used to determine the influence of pain on fatigue. Sample was composed of 32 PMS diagnosed with relapsing remitting type. Muscle pain was the most common type of pain reported by participants (40%). Pain correlated strongly only with fatigue and explained 28% (R2 = 0.28) of the variance in fatigue scores. This study showed strong association between muscle pain and fatigue (r = - 0.52; p <0.01), and no association between pain and UL function.
- 9 March 2025
- Published by Revista Interfaces: Saude, Humanas e Technologia in Revista Interfaces: Saúde, Humanas E Tecnologia
- Vol. 12 (4) , 4749-4759
Open AccessASSOCIATION BETWEEN PAIN AND FATIGUE IN BRAZILIAN PEOPLE WITH MULTIPLE SCLEROSIS: A CROSS‐SECTIONAL STUDY
The impact of pain and fatigue on the upper limb (UL) function of people with Multiple Sclerosis (PMS) is well-known, but the relations between them are poorly understood. This study aimed to verify the frequency of the types of pain and the relationship between pain and factors that limit UL function in PMS. This was a descriptive, cross-sectional study. Pain was evaluated by Functional Assessment of Quality of Life in PMS. UL function was evaluated by the hand grip strength and by the Test d’ Evaluation de la performance des Membres Supérieurs des Personnes Âgées (TEMPA), while the fatigue was evaluated by the Modified Fatigue Impact Scale. Correlations between pain and the other variables were analyzed with the Pearson coefficient. A simple linear regression was used to determine the influence of pain on fatigue. Sample was composed of 32 PMS diagnosed with relapsing remitting type. Muscle pain was the most common type of pain reported by participants (40%). Pain correlated strongly only with fatigue and explained 28% (R2 = 0.28) of the variance in fatigue scores. This study showed strong association between muscle pain and fatigue (r = - 0.52; p <0.01), and no association between pain and UL function. Keywords: Demyelination; symptoms; relations The impact of pain and fatigue on the upper limb (UL) function of people with Multiple Sclerosis (PMS) is well-known, but the relations between them are poorly understood. This study aimed to verify the frequency of the types of pain and the relationship between pain and factors that limit UL function in PMS. This was a descriptive, cross-sectional study. Pain was evaluated by Functional Assessment of Quality of Life in PMS. UL function was evaluated by the hand grip strength and by the Test d’ Evaluation de la performance des Membres Supérieurs des Personnes Âgées (TEMPA), while the fatigue was evaluated by the Modified Fatigue Impact Scale. Correlations between pain and the other variables were analyzed with the Pearson coefficient. A simple linear regression was used to determine the influence of pain on fatigue. Sample was composed of 32 PMS diagnosed with relapsing remitting type. Muscle pain was the most common type of pain reported by participants (40%). Pain correlated strongly only with fatigue and explained 28% (R2 = 0.28) of the variance in fatigue scores. This study showed strong association between muscle pain and fatigue (r = - 0.52; p <0.01), and no association between pain and UL function.
- Open Access
- 1 August 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (S 01) , S1-S52
Use of mobile app to monitor patients with multiple sclerosis
Address for correspondence: Carlos Bernardo Tauil (email: cbtauil@gmail.com). Abstract Advances and modernization of technology in healthcare have led to improvements in the treatment of serious, long-term illnesses such as multiple sclerosis (MS). Access to technological resources has facilitated the care and monitoring of patients undergoing treatment for MS and consequent adherence to the use of prescribed medications, in addition to controlling adverse reactions and monitoring relapses. Furthermore, it facilitates greater integration between the medical and multidisciplinary teams and the people with MS under monitoring. 1. Development of Clinical Protocols • MS Protocol • Development of Questionnaires (PHQ-9, GAD-7, AUDIT-C [alcohol use], NHANES [education], smoking [score], Epworth Sleepiness Scale, CSAT, Uhtlhoff phenomenon, sexual dysfunction, urinary and intestinal symptoms, sleep pattern, PDDS and MFIS) 2. Structuring dynamic forms • Data structuring of dynamic forms • Created dynamic historical record form for the patient’s medical record • Created dynamic Infusion Record form 3. Coupled the dynamic historical record form until patient inclusion • The clinical information already recorded on patients was recorded from diagnosis until the moment the form was filled out (Form information; Date of MS diagnosis, Phenotype, Outbreaks, EDSS, 9HPT, T2SFW, DMD, MRI, and other results) • Added the event (scheduling the infusion with the medication the patient used) • Added the infusion protocol (When the protocol is added, the patient receives preinfusion exam requests) • Infusion record (it is a dynamic form that the nursing team needs to fill out at each patient’s infusion with relevant data during the infusion, such as: date of current infusion, SVR, infusion cycle, medication, route of administration, complications during the infusion, among other information). The application proved to be useful for most people with multiple sclerosis who started using it regularly. The medical and multidisciplinary team also recognized benefits regarding patient monitoring. Article published online: 02 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 1 August 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (S 01) , S1-S52
Open AccessUse of mobile app to monitor patients with multiple sclerosis
Address for correspondence: Carlos Bernardo Tauil (email: cbtauil@gmail.com). Abstract Advances and modernization of technology in healthcare have led to improvements in the treatment of serious, long-term illnesses such as multiple sclerosis (MS). Access to technological resources has facilitated the care and monitoring of patients undergoing treatment for MS and consequent adherence to the use of prescribed medications, in addition to controlling adverse reactions and monitoring relapses. Furthermore, it facilitates greater integration between the medical and multidisciplinary teams and the people with MS under monitoring. 1. Development of Clinical Protocols • MS Protocol • Development of Questionnaires (PHQ-9, GAD-7, AUDIT-C [alcohol use], NHANES [education], smoking [score], Epworth Sleepiness Scale, CSAT, Uhtlhoff phenomenon, sexual dysfunction, urinary and intestinal symptoms, sleep pattern, PDDS and MFIS) 2. Structuring dynamic forms • Data structuring of dynamic forms • Created dynamic historical record form for the patient’s medical record • Created dynamic Infusion Record form 3. Coupled the dynamic historical record form until patient inclusion • The clinical information already recorded on patients was recorded from diagnosis until the moment the form was filled out (Form information; Date of MS diagnosis, Phenotype, Outbreaks, EDSS, 9HPT, T2SFW, DMD, MRI, and other results) • Added the event (scheduling the infusion with the medication the patient used) • Added the infusion protocol (When the protocol is added, the patient receives preinfusion exam requests) • Infusion record (it is a dynamic form that the nursing team needs to fill out at each patient’s infusion with relevant data during the infusion, such as: date of current infusion, SVR, infusion cycle, medication, route of administration, complications during the infusion, among other information). The application proved to be useful for most people with multiple sclerosis who started using it regularly. The medical and multidisciplinary team also recognized benefits regarding patient monitoring. Article published online: 02 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 1 January 2023
- Published by Editora SORIAN
- p. 391-405
DISCUSSÃO
- Open Access
- 28 July 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-7
Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic
Early predictions forecasted large numbers of severe acute respiratory syndrome coronavirus (SARS-CoV-2) cases and associated deaths in Africa. To date, Africa has been relatively spared. Various hypotheses were postulated to explain the lower than anticipated impact on public health in Africa. However, the contribution of pre-existing immunity is yet to be investigated. In this study, the presence of antibodies against SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in pre-pandemic samples from Africa, Europe, South and North America was examined by ELISA. The protective efficacy of N specific antibodies isolated from Central African donors was tested by in vitro neutralization and in a mouse model of SARS-CoV-2 infection. Antibodies against SARS-CoV-2 S and N proteins were rare in all populations except in Gabon and Senegal where N specific antibodies were prevalent. However, these antibodies failed to neutralize the virus either in vitro or in vivo. Overall, this study indicates that cross-reactive immunity against SARS-CoV-2 N protein was present in Africa prior to the pandemic. However, this pre-existing humoral immunity does not impact viral fitness in rodents suggesting that other human immune defense mechanisms could be involved. In Africa, seroprevalence studies using the N protein are over-estimating SARS-CoV-2 circulation.
- 28 July 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-7
Open AccessCross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic
Early predictions forecasted large numbers of severe acute respiratory syndrome coronavirus (SARS-CoV-2) cases and associated deaths in Africa. To date, Africa has been relatively spared. Various hypotheses were postulated to explain the lower than anticipated impact on public health in Africa. However, the contribution of pre-existing immunity is yet to be investigated. In this study, the presence of antibodies against SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in pre-pandemic samples from Africa, Europe, South and North America was examined by ELISA. The protective efficacy of N specific antibodies isolated from Central African donors was tested by in vitro neutralization and in a mouse model of SARS-CoV-2 infection. Antibodies against SARS-CoV-2 S and N proteins were rare in all populations except in Gabon and Senegal where N specific antibodies were prevalent. However, these antibodies failed to neutralize the virus either in vitro or in vivo. Overall, this study indicates that cross-reactive immunity against SARS-CoV-2 N protein was present in Africa prior to the pandemic. However, this pre-existing humoral immunity does not impact viral fitness in rodents suggesting that other human immune defense mechanisms could be involved. In Africa, seroprevalence studies using the N protein are over-estimating SARS-CoV-2 circulation.
- Open Access
- 1 November 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (11) , 1049-1061
Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system
The Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently.
- 1 November 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (11) , 1049-1061
Open AccessRecommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system
The Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently.
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (1) , 44-50
The impact of physical functions on depressive symptoms in people with multiple sclerosis
Background: Multiple sclerosis (MS) is an immune-mediated disease that affects the central nervous system. The impact of MS transcends physical functions and extends to psychological impairment. Approximately 50% of people with MS develop depressive symptoms during their lifetime and depressive symptoms may predict impairment of physical functions. However, prediction of depressive symptoms based on objective measures of physical functions is still necessary. Objective: To compare physical functions between people with MS presenting depressive symptoms or not and to identify predictors of depressive symptoms using objective measures of physical functions. Methods: Cross-sectional study including 26 people with MS. Anxiety and/or depressive symptoms were assessed by the Beck Depression Inventory-II (BDI-II) and by the Hospital Anxiety and Depression Scale (HADS). Outcomes of physical functions included: the Nnnine-hole Ppeg Ttest (NHPT), knee muscle strength, balance control, the Timed Up and Go Test (TUG), and the 6-minute walk test (6MWT). Perceived exertion was measured using the Borg scale. Results: The frequency of depressive symptoms was 42% in people with MS. Balance control during a more challenging task was impaired in people with MS who presented depressive symptoms. Balance could explain 21-24% of the variance in depressive symptoms. 6MWT and TUG presented a trend of significance explaining 16% of the variance in the BDI-II score. Conclusions: Impairment in physical functions consists in a potential predictor of depressive symptoms in people with MS. Exercise interventions aiming at the improvement of physical functions, together with the treatment of depressive symptoms and conventional medical treatment, are suggested.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (1) , 44-50
Open AccessThe impact of physical functions on depressive symptoms in people with multiple sclerosis
Background: Multiple sclerosis (MS) is an immune-mediated disease that affects the central nervous system. The impact of MS transcends physical functions and extends to psychological impairment. Approximately 50% of people with MS develop depressive symptoms during their lifetime and depressive symptoms may predict impairment of physical functions. However, prediction of depressive symptoms based on objective measures of physical functions is still necessary. Objective: To compare physical functions between people with MS presenting depressive symptoms or not and to identify predictors of depressive symptoms using objective measures of physical functions. Methods: Cross-sectional study including 26 people with MS. Anxiety and/or depressive symptoms were assessed by the Beck Depression Inventory-II (BDI-II) and by the Hospital Anxiety and Depression Scale (HADS). Outcomes of physical functions included: the Nnnine-hole Ppeg Ttest (NHPT), knee muscle strength, balance control, the Timed Up and Go Test (TUG), and the 6-minute walk test (6MWT). Perceived exertion was measured using the Borg scale. Results: The frequency of depressive symptoms was 42% in people with MS. Balance control during a more challenging task was impaired in people with MS who presented depressive symptoms. Balance could explain 21-24% of the variance in depressive symptoms. 6MWT and TUG presented a trend of significance explaining 16% of the variance in the BDI-II score. Conclusions: Impairment in physical functions consists in a potential predictor of depressive symptoms in people with MS. Exercise interventions aiming at the improvement of physical functions, together with the treatment of depressive symptoms and conventional medical treatment, are suggested.
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 54 (3) , e10428
Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments
There is increasing evidence that neurofilament light chain (NF-L) can be considered as a biomarker for neuro-axonal damage. This polypeptide can be released into the cerebrospinal fluid (CSF) and the blood, where it can be quantified. The concentration of NF-L is elevated in patients with multiple sclerosis (MS) and psychiatric disorders. We aimed to investigate the NF-L levels in the CSF from treated MS patients and the relationship with depression or anxiety. The study involved three groups: control group (individuals without inflammation), the relapse-remitting multiple sclerosis (RRMS)-untreated group, and the RRMS-Fingo group (RRMS patients who were treated with fingolimod). MS disability was assessed by the Expanded Disability Status Scale, and depression and anxiety were evaluated by a neuropsychologist, using the Hospital Anxiety and Depression Scale, the Beck Depression Inventory-II, and the Beck Anxiety Inventory. Individual CSF samples were collected to measure NF-L levels. The results of the statistical analysis on levels of NF-L in the CSF of control subjects, RRMS-untreated patients, and RRMS-Fingo patients were significant. The relationship between depression and anxiety in RRMS-Fingo patients and NF-L levels was not statistically significant. In conclusion, MS events such as anxiety and depression appear to contribute to the onset of clinical relapses, subclinical cases, and neurodegeneration.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 54 (3) , e10428
Open AccessDepression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments
There is increasing evidence that neurofilament light chain (NF-L) can be considered as a biomarker for neuro-axonal damage. This polypeptide can be released into the cerebrospinal fluid (CSF) and the blood, where it can be quantified. The concentration of NF-L is elevated in patients with multiple sclerosis (MS) and psychiatric disorders. We aimed to investigate the NF-L levels in the CSF from treated MS patients and the relationship with depression or anxiety. The study involved three groups: control group (individuals without inflammation), the relapse-remitting multiple sclerosis (RRMS)-untreated group, and the RRMS-Fingo group (RRMS patients who were treated with fingolimod). MS disability was assessed by the Expanded Disability Status Scale, and depression and anxiety were evaluated by a neuropsychologist, using the Hospital Anxiety and Depression Scale, the Beck Depression Inventory-II, and the Beck Anxiety Inventory. Individual CSF samples were collected to measure NF-L levels. The results of the statistical analysis on levels of NF-L in the CSF of control subjects, RRMS-untreated patients, and RRMS-Fingo patients were significant. The relationship between depression and anxiety in RRMS-Fingo patients and NF-L levels was not statistically significant. In conclusion, MS events such as anxiety and depression appear to contribute to the onset of clinical relapses, subclinical cases, and neurodegeneration.
- 1 October 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 45, 102435
Efficacy outcomes reported in trials of multiple sclerosis: A systematic scoping review
- 1 October 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 45, 102435
Efficacy outcomes reported in trials of multiple sclerosis: A systematic scoping review
- 1 August 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 43, 102203
Effect of hippotherapy on walking performance and gait parameters in people with multiple sclerosis
- 1 August 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 43, 102203
Effect of hippotherapy on walking performance and gait parameters in people with multiple sclerosis